Trial
NCT01900665
Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Eli Lilly and Company
Collaborators
—
Condition
Alzheimer's Disease
Intervention
Solanezumab
Why stopped
Solanezumab did not meet the study's primary endpoint.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-10-09